Scientists report the efficacy of anti-programmed death 1 antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced natural killer/T cell lymphoma.
[Signal Transduction and Targeted Therapy]
6445218
{6445218:NIW37BLL}
apa
50
1
157586
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-d023d23f070bc30f0d18ff5398a36cfc%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22NIW37BLL%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cai%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECai%2C%20J.%2C%20Liu%2C%20P.%2C%20Huang%2C%20H.%2C%20Li%2C%20Y.%2C%20Ma%2C%20S.%2C%20Zhou%2C%20H.%2C%20Tian%2C%20X.%2C%20Zhang%2C%20Y.%2C%20Gao%2C%20Y.%2C%20Xia%2C%20Y.%2C%20Zhang%2C%20X.%2C%20Yang%2C%20H.%2C%20Li%2C%20L.%2C%20%26amp%3B%20Cai%2C%20Q.%20%282020%29.%20Combination%20of%20anti-PD-1%20antibody%20with%20P-GEMOX%20as%20a%20potentially%20effective%20immunochemotherapy%20for%20advanced%20natural%20killer%5C%2FT%20cell%20lymphoma.%20%3Ci%3ESignal%20Transduction%20and%20Targeted%20Therapy%3C%5C%2Fi%3E%2C%20%3Ci%3E5%3C%5C%2Fi%3E%281%29%2C%201%26%23x2013%3B9.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41392-020-00331-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41392-020-00331-3%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DNIW37BLL%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Combination%20of%20anti-PD-1%20antibody%20with%20P-GEMOX%20as%20a%20potentially%20effective%20immunochemotherapy%20for%20advanced%20natural%20killer%5C%2FT%20cell%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panpan%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huiqiang%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yajun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuyun%22%2C%22lastName%22%3A%22Ma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hui%22%2C%22lastName%22%3A%22Zhou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaopeng%22%2C%22lastName%22%3A%22Tian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuchen%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yan%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Xia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xuanye%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hang%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lirong%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qingqing%22%2C%22lastName%22%3A%22Cai%22%7D%5D%2C%22abstractNote%22%3A%22Advanced%20natural%20killer%5C%2FT%20cell%20lymphoma%20%28NKTL%29%20has%20demonstrated%20poor%20prognosis%20with%20currently%20available%20therapies.%20Here%2C%20we%20report%20the%20efficacy%20of%20anti-programmed%20death%201%20%28PD-1%29%20antibody%20with%20the%20P-GEMOX%20%28pegaspargase%2C%20gemcitabine%2C%20and%20oxaliplatin%29%20regimen%20in%20advanced%20NKTL.%20Nine%20patients%20underwent%20six%2021-day%20cycles%20of%20anti-PD-1%20antibody%20%28day%201%29%2C%20pegaspargase%202000%5Cu2009U%5C%2Fm2%20%28day%201%29%2C%20gemcitabine%201%5Cu2009g%5C%2Fm2%20%28days%201%20and%208%29%20and%20oxaliplatin%20130%5Cu2009mg%5C%2Fm2%20%28day%201%29%2C%20followed%20by%20anti-PD-1%20antibody%20maintenance%20every%203%20weeks.%20Programmed%20death-ligand%201%20%28PD-L1%29%20expression%20and%20genetic%20alterations%20were%20determined%20in%20paraffin-embedded%20pretreatment%20tissue%20samples%20using%20immunohistochemistry%20and%20next-generation%20sequencing%20%28NGS%29%20analysis.%20Responses%20were%20assessed%20using%2018F-fluorodeoxyglucose%20positron%20emission%20tomography%20%2818FDG-PET%29%20and%20computed%20tomography%20or%20magnetic%20resonance%20imaging.%20Eight%20patients%20exhibited%20significant%20responses%2C%20comprising%20of%20seven%20complete%20remissions%20and%20one%20partial%20remission%20%28overall%20response%20rate%3A%2088.9%25%29.%20After%20a%20median%20follow-up%20of%2010.6%20months%2C%206%5C%2F9%20patients%20%2866.7%25%29%20remained%20in%20complete%20remission.%20The%20most%20common%20grade%203%5C%2F4%20adverse%20events%20were%20anemia%20%2833.3%25%29%2C%20neutropenia%20%2833.3%25%29%2C%20and%20thrombocytopenia%20%2833.3%25%29%3B%20all%20of%20which%20were%20manageable%20and%20resolved.%20Immunochemotherapy%20produced%20a%20high%20response%20rate%20in%20patients%20with%20positive%20PD-L1%20expression%20%285%5C%2F6%2C%2083.3%25%29.%20NGS%20analysis%20suggested%20that%20STAT3%5C%2FJAK3%5C%2FPD-L1%20alterations%20and%20ARID1A%20mutation%20were%20associated%20with%20immunochemotherapy%20efficacy.%20Mutation%20in%20DDX3X%20and%20alteration%20in%20epigenetic%20modifiers%20of%20KMT2D%2C%20TET2%2C%20and%20BCORL1%20might%20indicate%20a%20poor%20response%20to%20immunochemotherapy.%20In%20conclusion%2C%20the%20anti-PD-1%20antibody%20plus%20P-GEMOX%20regimen%20demonstrated%20promising%20efficacy%20in%20advanced%20NKTL.%20PD-L1%20expression%20combined%20with%20specific%20genetic%20alterations%20could%20be%20used%20as%20potential%20biomarkers%20to%20predict%20therapeutic%20responses%20to%20immunochemotherapy.%22%2C%22date%22%3A%222020-12-30%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41392-020-00331-3%22%2C%22ISSN%22%3A%222059-3635%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41392-020-00331-3%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-01-05T03%3A17%3A49Z%22%7D%7D%5D%7D
Cai, J., Liu, P., Huang, H., Li, Y., Ma, S., Zhou, H., Tian, X., Zhang, Y., Gao, Y., Xia, Y., Zhang, X., Yang, H., Li, L., & Cai, Q. (2020). Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduction and Targeted Therapy, 5(1), 1–9. https://doi.org/10.1038/s41392-020-00331-3 Cite
